Date: 2014-02-12
Type of information: Distribution agreement
Compound: Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes
Company: Horizon Discovery (UK) Haplogen (Austria)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism:
Disease:
Details: * On February 12, 2014, Horizon Discovery, a provider of research tools to support translational genomics and the development of personalized medicines, has announced it has signed a worldwide distribution agreement with Haplogen, with immediate effect. Under the terms of the agreement customers can now access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. This agreement represents the first time that Horizon will be distributing another company’s products, recognizing Horizon’s past success in penetrating the global model cell lines market.
Haploid cellular models offer a biologically relevant system for in vitro genetic analyses of molecular, cellular, and developmental events in various cell lineages. Haplogen’s Haploid Gene Trap Mutant Collection is the largest haploid cell line bank available, and comprises over 9,400 mutant clones, affecting over 3,700 human genes and an additional 1,600 inducible clones covering 1,100 genes. For-profit customers will be able to access the cell-line bank by signing an annual limited use label license, whilst academic customers will be able to access an unlimited term license and will receive a greater than 90% discount.
Financial terms:
Latest news:
